E U R O P E A N U R O L O G Y 6 1 ( 2 0 1 2 ) e 1 5
ava i lable at www.sciencedirect .com
journal homepage: www.europeanurology.com
Letter to the Editor
Reply to Apul Goel and Sagorika Paul’s Letter to the
Editor re: Tim O’Brien, Eleanor Ray, Rajinder Singh, Bola
Coker, Ralph Beard, British Association of Urological
Surgeons Section of Oncology. Prevention of Bladder
Tumours after Nephroureterectomy for Primary Upper
Urinary Tract Urothelial Carcinoma: A Prospective,
Multicentre, Randomised Clinical Trial of a Single Post-
operative Intravesical Dose of Mitomycin C (the ODMIT-
C Trial). Eur Urol 2011;60:703–10
The authors’ suggestion of preoperative intravesical mito-
mycin C (MMC) is interesting but purely speculative. There
is not a shred of evidence to support its use in this way. Let’s
get single-dose postoperative MMC embedded into routine
DOIs of original articles: 10.1016/j.eururo.2011.05.064, 10.1016/j.eururo.201
0302-2838/$ – see back matter # 2011 Published by Elsevier B.V. on behalf
urologic practice first, as it is supported by the level 1
evidence of the ODMIT-C trial, and then start exploring
novel approaches.
Conflicts of interest: The author has nothing to disclose.
Tim O’Brien*
Urology Centre, Guys Hospital, London, SE1 9RT, United Kingdom
*Tel. +44 20 71887338; Fax: +44 20 71886787
E-mail address: [email protected]
November 21, 2011
Published online on December 2, 2011
1.11.037
of European Association of Urology. doi:10.1016/j.eururo.2011.11.036
